{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Afrezza+%28insulin+human%29+Inhalation+Powder&page=2",
    "query": {
      "intervention": "Afrezza (insulin human) Inhalation Powder",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 44,
    "total_pages": 5,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Afrezza+%28insulin+human%29+Inhalation+Powder&page=3&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Afrezza+%28insulin+human%29+Inhalation+Powder&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-04T00:50:39.487Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01451398",
      "title": "Comparison of Technosphere® Insulin Versus Technosphere Powder (Placebo) in Insulin-Naive Subjects With Type 2 Diabetes Mellitus",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Type 2 Diabetes"
      ],
      "interventions": [
        {
          "name": "Technosphere® Insulin",
          "type": "DRUG"
        },
        {
          "name": "Technosphere Powder",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mannkind Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 353,
      "start_date": "2011-11",
      "completion_date": "2013-07",
      "has_results": true,
      "last_update_posted_date": "2014-10-17",
      "last_synced_at": "2026-10-04T00:50:39.487Z",
      "location_count": 50,
      "location_summary": "Anaheim, California • Huntington Beach, California • Laguna Hills, California + 41 more",
      "locations": [
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Huntington Beach",
          "state": "California"
        },
        {
          "city": "Laguna Hills",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01451398"
    },
    {
      "nct_id": "NCT00391209",
      "title": "Compare Two Dosing Algorithms in Insulin-Naive Patients With Type 2 Diabetes Mellitus",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Diabetes Mellitus, Type 2"
      ],
      "interventions": [
        {
          "name": "simplified diabetes regimen starting with a fixed dose of Human Insulin Inhalation Powder",
          "type": "DRUG"
        },
        {
          "name": "intensive diabetes management starting with an adjusted dose of Human Insulin Inhalation Powder",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 379,
      "start_date": "2006-10",
      "completion_date": "2008-05",
      "has_results": false,
      "last_update_posted_date": "2018-03-09",
      "last_synced_at": "2026-10-04T00:50:39.487Z",
      "location_count": 17,
      "location_summary": "Santa Ana, California • Washington D.C., District of Columbia • Hollywood, Florida + 14 more",
      "locations": [
        {
          "city": "Santa Ana",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Hollywood",
          "state": "Florida"
        },
        {
          "city": "New Port Richey",
          "state": "Florida"
        },
        {
          "city": "South Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00391209"
    },
    {
      "nct_id": "NCT01798914",
      "title": "Patient Transitioning From Exubera® Inhalation Powder to Technosphere® Insulin Inhalation Powder",
      "overall_status": "NO_LONGER_AVAILABLE",
      "study_type": "EXPANDED_ACCESS",
      "phases": [],
      "conditions": [
        "Type 1 Diabetes",
        "Type 2 Diabetes"
      ],
      "interventions": [
        {
          "name": "Technosphere Insulin Inhalation Powder",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mannkind Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": null,
      "start_date": "2008-10",
      "completion_date": "2015-05",
      "has_results": false,
      "last_update_posted_date": "2016-01-20",
      "last_synced_at": "2026-10-04T00:50:39.487Z",
      "location_count": 14,
      "location_summary": "Montgomery, Alabama • Miami, Florida • Orland Park, Illinois + 10 more",
      "locations": [
        {
          "city": "Montgomery",
          "state": "Alabama"
        },
        {
          "city": "Montgomery",
          "state": "Alabama"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Orland Park",
          "state": "Illinois"
        },
        {
          "city": "Shreveport",
          "state": "Louisiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01798914"
    },
    {
      "nct_id": "NCT00700622",
      "title": "Safety and Efficacy of Technosphere® Insulin Inhalation Powder and Lantus® Compared to Humalog® and Lantus® Over 16-Weeks",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Diabetes, Type 1"
      ],
      "interventions": [
        {
          "name": "Technosphere Insulin",
          "type": "DRUG"
        },
        {
          "name": "Insulin glargine",
          "type": "DRUG"
        },
        {
          "name": "Insulin lispro",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mannkind Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 130,
      "start_date": "2008-05",
      "completion_date": "2010-03",
      "has_results": true,
      "last_update_posted_date": "2014-10-16",
      "last_synced_at": "2026-10-04T00:50:39.487Z",
      "location_count": 20,
      "location_summary": "Huntington Beach, California • La Jolla, California • San Mateo, California + 14 more",
      "locations": [
        {
          "city": "Huntington Beach",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "San Mateo",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00700622"
    },
    {
      "nct_id": "NCT00426920",
      "title": "Investigating the Pharmacokinetics and Pharmacodynamics of Recombinant Human Insulin Administered by Dry Powder Inhaler",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Diabetes Mellitus"
      ],
      "interventions": [
        {
          "name": "Insulin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "QDose Limited",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "MALE",
        "summary": "18 Years to 45 Years · Male only"
      },
      "enrollment_count": 14,
      "start_date": "2007-02",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2007-01-25",
      "last_synced_at": "2026-10-04T00:50:39.487Z",
      "location_count": 1,
      "location_summary": "Chula Vista, California",
      "locations": [
        {
          "city": "Chula Vista",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00426920"
    },
    {
      "nct_id": "NCT04974528",
      "title": "Afrezza® INHALE-1 Study in Pediatrics",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Diabetes Mellitus, Type 1",
        "Diabetes Mellitus, Type 2"
      ],
      "interventions": [
        {
          "name": "Afrezza",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Rapid-acting Insulin Analog",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Basal Insulin",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Mannkind Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "4 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "4 Years to 17 Years"
      },
      "enrollment_count": 319,
      "start_date": "2021-09-29",
      "completion_date": "2025-04-29",
      "has_results": false,
      "last_update_posted_date": "2025-05-06",
      "last_synced_at": "2026-10-04T00:50:39.487Z",
      "location_count": 39,
      "location_summary": "Los Angeles, California • Orange, California • Palo Alto, California + 35 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04974528"
    },
    {
      "nct_id": "NCT00325364",
      "title": "Study of Human Insulin Inhalation Powder in Patients With Type 2 Diabetes",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Diabetes Mellitus, Type 2"
      ],
      "interventions": [
        {
          "name": "Human Insulin Inhalation Powder",
          "type": "DRUG"
        },
        {
          "name": "Injectable insulin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 415,
      "start_date": "2006-04",
      "completion_date": "2008-05",
      "has_results": false,
      "last_update_posted_date": "2019-09-16",
      "last_synced_at": "2026-10-04T00:50:39.487Z",
      "location_count": 9,
      "location_summary": "Sacramento, California • Santa Ana, California • Jacksonville, Florida + 6 more",
      "locations": [
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Santa Ana",
          "state": "California"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Baton Rouge",
          "state": "Louisiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00325364"
    },
    {
      "nct_id": "NCT04849845",
      "title": "Afrezza® Dosing Optimization Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Diabetes Mellitus, Type 1",
        "Diabetes Mellitus, Type 2"
      ],
      "interventions": [
        {
          "name": "Afrezza Dose 1",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "Afrezza Dose 2",
          "type": "COMBINATION_PRODUCT"
        }
      ],
      "intervention_types": [
        "COMBINATION_PRODUCT"
      ],
      "sponsor": "Mannkind Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2021-04-09",
      "completion_date": "2021-05-28",
      "has_results": true,
      "last_update_posted_date": "2023-09-18",
      "last_synced_at": "2026-10-04T00:50:39.487Z",
      "location_count": 2,
      "location_summary": "Escondido, California • Walnut Creek, California",
      "locations": [
        {
          "city": "Escondido",
          "state": "California"
        },
        {
          "city": "Walnut Creek",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04849845"
    },
    {
      "nct_id": "NCT01021891",
      "title": "A Study to Evaluate Insulin in the Blood After Inhalation of a Dry Powder Insulin Formulation (Called Technosphere®/Insulin) in Non-diabetic Patients With & Without Chronic Obstructive Pulmonary Disease (COPD)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Chronic Obstructive Pulmonary Disease (COPD)"
      ],
      "interventions": [
        {
          "name": "Technosphere®/Insulin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mannkind Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 39,
      "start_date": "2006-07",
      "completion_date": "2008-11",
      "has_results": false,
      "last_update_posted_date": "2013-12-17",
      "last_synced_at": "2026-10-04T00:50:39.487Z",
      "location_count": 1,
      "location_summary": "San Antonio, Texas",
      "locations": [
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01021891"
    },
    {
      "nct_id": "NCT00150410",
      "title": "Demonstrate Exubera Works As Well As Avandia When Added To Sulfonylurea + Metformin In Controlling Glucose",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Diabetes Mellitus"
      ],
      "interventions": [
        {
          "name": "Inhaled insulin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 626,
      "start_date": "2003-01",
      "completion_date": "2007-06",
      "has_results": false,
      "last_update_posted_date": "2008-10-31",
      "last_synced_at": "2026-10-04T00:50:39.487Z",
      "location_count": 88,
      "location_summary": "Mesa, Arizona • Phoenix, Arizona • Tucson, Arizona + 72 more",
      "locations": [
        {
          "city": "Mesa",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Searcy",
          "state": "Arkansas"
        },
        {
          "city": "Alhambra",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00150410"
    }
  ]
}